<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10483</article-id><article-id pub-id-type="doi">10.7554/eLife.10483</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-39627"><name><surname>Conery</surname><given-names>Andrew R</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-39628"><name><surname>Centore</surname><given-names>Richard C</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-39629"><name><surname>Neiss</surname><given-names>Adrianne</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-39630"><name><surname>Keller</surname><given-names>Patricia J</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-39631"><name><surname>Joshi</surname><given-names>Shivangi</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-46906"><name><surname>Spillane</surname><given-names>Kerry L</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-39632"><name><surname>Sandy</surname><given-names>Peter</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-37281"><name><surname>Hatton</surname><given-names>Charlie</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-39633"><name><surname>Pardo</surname><given-names>Eneida</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-39634"><name><surname>Zawadzke</surname><given-names>Laura</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-39635"><name><surname>Bommi-Reddy</surname><given-names>Archana</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-39636"><name><surname>Gascoigne</surname><given-names>Karen E</given-names></name><aff><institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-37277"><name><surname>Bryant</surname><given-names>Barbara M</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-37278"><name><surname>Mertz</surname><given-names>Jennifer A</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" corresp="yes" id="author-37282"><name><surname>Sims</surname><given-names>Robert J</given-names></name><aff><institution>Constellation Pharmaceuticals</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country><email>robert.sims@constellationpharma.com</email></aff><xref ref-type="fn" rid="conf16"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-30083"><name><surname>Armstrong</surname><given-names>Scott A</given-names></name><role>Reviewing editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>01</month><year>2016</year></pub-date><volume>5</volume><elocation-id>e10483</elocation-id><supplementary-material><ext-link xlink:href="elife-10483-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>30</day><month>07</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>01</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Conery et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Conery et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demonstrate that CBP/EP300 bromodomain inhibition preferentially abrogates the viability of multiple myeloma cell lines. Selective targeting of multiple myeloma cell lines through CBP/EP300 bromodomain inhibition is the result of  direct transcriptional suppression of the lymphocyte-specific transcription factor IRF4, which is essential for the viability of myeloma cells, and the concomitant repression of the IRF4 target gene <italic>c-MYC</italic>. Ectopic expression of either IRF4 or MYC antagonizes the phenotypic and transcriptional effects of CBP/EP300 bromodomain inhibition, highlighting the IRF4/MYC axis as a key component of its mechanism of action. These findings suggest that CBP/EP300 bromodomain inhibition represents a viable therapeutic strategy for targeting multiple myeloma and other lymphoid malignancies dependent on the IRF4 network.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Andrew R Conery, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf3"><p>Richard C Centore, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf4"><p>Adrianne Neiss, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf5"><p>Patricia J Keller, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf6"><p>Shivangi Joshi, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf7"><p>Kerry L Spillane, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf8"><p>Peter Sandy, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf9"><p>Charlie Hatton, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf10"><p>Eneida Pardo, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf11"><p>Laura Zawadzke, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf12"><p>Archana Bommi-Reddy, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf13"><p>Karen E Gascoigne, Employee of Genentech.</p></fn><fn fn-type="conflict" id="conf14"><p>Barbara M Bryant, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf15"><p>Jennifer A Mertz, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf16"><p>Robert J Sims, Employee of Constellation Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></back></article>